Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hygeia Therapeutics completes preclinical studies of HYG-102

Nov. 12, 2010

FDA approves Egrifta for lipodystrophy in HIV-infected patients

Nov. 12, 2010

Repros Therapeutics reports on type B meeting with FDA regarding Androxal

Nov. 12, 2010

Bionovo receives FDA approval for clinical development plan for Menerba

Nov. 12, 2010

Patient screening complete for phase III rhGAD65 trial in type 1 diabetes

Nov. 10, 2010

ECLIPSE trial compares Epanova with Lovaza

Nov. 10, 2010

In vivo data support potential of galantamine for treatment of obesity and related complications

Nov. 10, 2010

Results reported from phase III BLOOM-DM weight loss study in type 2 diabetes

Nov. 9, 2010

Ardea Biosciences reports data on RDEA-594 in gout

Nov. 9, 2010

Phase IIb data reported on LIPO-102 for selective nonablative fat reduction

Nov. 8, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...